This ETF offers targeted exposure to the biotech industry, a corner of the health care sector that is capable of delivering big returns but also exhibiting significant volatility. Given that risk/return profile, accessing biotech through the exchange-traded wrapper has some obvious appeal; it allows investors to spread out exposure, thereby increasing the opportunity of holding a stock that hits it big. Given that targeted objective, this ETF is probably most useful for those seeking tactical exposure to this corner of the market; the underlying holdings are generally found in broad-based equity ETFs, so there should be little appeal to buy-and-holders. BBH used to be structured as a HOLRDS offered by Merrill Lynch, and converted to a true ETF in 2011. It should be noted, however, that this fund still maintains some of the concentration that was characteristic of HOLDS; a few stocks receive significant allocations in the portfolio, and the top ten holdings combine to make up the majority of assets. There are some other biotech ETFs out there that may be interesting opportunities, including IBB, XBI, FBT, and PBE. Those looking for a deep, balanced portfolio will probably prefer to avoid this Market Vectors ETF and utilize a fund such as IBB or XBI instead.
The adjacent table gives investors an individual Realtime Rating for BBH on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.View the Category Report
The following tables and charts contain in-depth metrics for this ETF and compare it to similar peer ETFs within its ETFdb.com Category.
This section compares how balanced and deep this ETF is relative to the peer group ETFdb.com Category.
|Developed Markets (ex-US)||11.5%|
This ETF is not currently available for commission free trading on any platforms.
There are 35 other ETFs in the Health & Biotech Equities ETFdb.com Category that are also eligible for commission free trading:
This section shows how this ETF has performed relative to its peer group ETFdb.com Category.
This section compares the fund flows of this ETF to peers in the same ETFdb.com Category.
The following charts can be customized to display historical performance in a number of different formats, including line charts, bar charts, and candlesticks. Time periods can be adjusted to increase or decrease the period shown, ranging from five minutes to several months.
The following chart also includes the option to compare the performance of BBH relative to other ETFs and benchmarks or to include indicators such as Bollinger Bands, relative strength, and moving averages.
This section shows how the volatility of this ETF compares to the peer group ETFdb.com Category.
Source: LSEG Information Services (US), Inc. (“LSEG”) © LSEG 2016. All rights in the XTF data, ratings and / or underlying data contained in this communication (“the XTF information”) vest in LSEG and/or its licensors. Neither LSEG nor its licensors accept any liability arising out of the use of, reliance on or any errors or omissions in the XTF information. No further distribution of the XTF information is permitted without LSEG’s express written consent. LSEG does not promote, sponsor or endorse the content of this communication.